TrialSignal
Clinical trial intelligence report
Pilot Study to Evaluate Clinically the Short-Term Efficacy of GlaucoT Glaucoma Treatment Glasses in the Treatment of Primary Open-Angle Glaucoma (GlaucoT)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 13, 2026
NCT ID
NCT05253534
Status
COMPLETED
Phase
Pilot Study
Sponsor
Glaucot Teknoloji Anonim Sirketi
Executive brief
Investment-Ready Snapshot
Glaucot Teknoloji Anonim Sirketi's GlaucoT glasses represent an innovative approach to treating POAG by utilizing flicker light therapy, which has shown promise in neuroprotection. Given the increasing prevalence of glaucoma, projected to affect over 60 million individuals globally, this device could address a significant unmet need in the market. The competitive landscape includes traditional IOP-lowering medications and surgical interventions, but GlaucoT's non-invasive, cost-effective solution may appeal to patients seeking alternatives. Successful outcomes could position Glaucot as a leader in glaucoma management, potentially leading to partnerships or licensing opportunities within the ophthalmic device sector.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05253534
Indication
Primary Open-Angle Glaucoma
Modality
medical device
Target
Flicker light therapy targeting neuroprotection and retinal ganglion cell preservation in primary open-angle glaucoma (POAG).
Intervention
GlaucoT Glaucoma Treatment Device
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.